Sickle cell disease is a genetic condition in which red
blood cells (RBCs) are unable to flow properly throughout the body due to their
misshapen form. This disease affects millions across the globe and over 100,000
here in the United States. While a change in a key protein is to blame for the
resulting effects, geneticists have been puzzled for many years in terms of finding
a cure.
Thanks to advances in modern technology, Pediatricians like
Erica Esrick can talk about existing sickle
cell treatments and ongoing clinical trials that show positive advancements
towards finding a cure through gene therapy. “Gene therapies seek to manipulate
the very information of life by replacing, inactivating, or fixing missing or
broken genes — and so curing patients. Despite gene therapy’s challenges, many
researchers believe sickle cell is a good target because the molecular pathways
are well understood and straightforward. What’s more, every copy of the gene
doesn’t need to be mended to have an effect” (Garcia de Jesus, 2022). Fetal
hemoglobin, a healthier form of hemoglobin, is being chosen to be the target of
gene therapy trials.
Preliminary data released in January 2021 showed that the
treatment helped six sickle cell patients make fetal hemoglobin. “Scientists
are testing other ways to tackle sickle cell via gene therapy, too. A
biotechnology company called bluebird bio is testing an approach that delivers
a functional copy of the HBB gene to patients. Another team is preparing to
begin a trial that will edit that gene directly using CRISPR/Cas9” (Garcia de
Jesus, 2022).
As someone who is headed into the healthcare field, it makes
me happy that I will have new treatments and cures to offer my patients who
suffer from this condition. I believe that in the years to come genetic treatments
and therapies will start to play a larger role in the healthcare industry. This
case is only the start of something revolutionary.
No comments:
Post a Comment